Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapy

Eosinophilic fasciitis is a rare connective tissue disease of unknown etiology. Therapeutic options include high-dose corticosteroids and other immunosuppressive drugs. We present a typical eosinophilic fasciitis case, which did not respond to first-line treatment, but improved remarkably after infliximab administration. This report demonstrates that in case of initial treatment failure, infliximab might be a relatively safe and effective way of eosinophilic fasciitis management.

Download Full-text

Delayed leukoencephalopathy from suspected polymer embolism after neuroendovascular procedures

The Neuroradiology Journal ◽

10.1177/19714009211029172 ◽

2021 ◽

pp. 197140092110291

Author(s):

Thomas Mellemkjær ◽

Ronil V Chandra ◽

Lasse Speiser ◽

Benedicte P Ulhøi ◽

Claus Z Simonsen

Keyword(s):

Polymer Material ◽

Endovascular Procedures ◽

Rare Complication ◽

Diagnostic Process ◽

Line Treatment ◽

Review Of The Literature ◽

First Line ◽

Stroke Treatment ◽

Oral Glucocorticoids ◽

First Line Treatment

As the neurointervention field grows, a new side effect emerges. Delayed leukoencephalopathy (DL) is believed to be an inflammatory or allergic reaction to polymer material that is shed from catheters during endovascular procedures. We present four cases of DL after aneurysm treatment in two patients, endovascular stroke treatment and diagnostic arteriography. We present our diagnostic process, including biopsy results in two patients, our anti-inflammatory treatment and outcomes together with a review of the literature. In our series, prognosis was variable with ongoing seizures in two patients. Our literature review reveals that asymptomatic shedding of polymer material is common, occurring in a third of endovascular stroke procedures, whereas symptomatic DL occurs in <0.5% of therapeutic neuroendovascular procedures. Clinicians should be aware of this rare complication, and oral glucocorticoids seem to be a reasonable first-line treatment strategy.

Download Full-text

Obstructive sleep apnea: A case report on uvulopalatopharyngoplasty and tongue reduction as a first line treatment modality in an underprivileged economic status

Dental Oral and Craniofacial Research ◽

10.15761/docr.1000252 ◽

2017 ◽

Vol 4 (3) ◽

Author(s):

Dayaratna J ◽

Nisahan B ◽

Wijesinghe S ◽

Peranantharajah T ◽

Samarasinghe B

Keyword(s):

Obstructive Sleep Apnea ◽

Case Report ◽

Sleep Apnea ◽

Treatment Modality ◽

Economic Status ◽

Line Treatment ◽

First Line ◽

Obstructive Sleep ◽

Tongue Reduction ◽

First Line Treatment

Download Full-text

Management of Pearly Penile Papules: A Review of the Literature

Journal of Cutaneous Medicine and Surgery ◽

10.1177/1203475419887730 ◽

2019 ◽

Vol 24 (1) ◽

pp. 79-85 ◽

Cited By ~ 1

Author(s):

Anthony D. Honigman ◽

Danielle P. Dubin ◽

Justin Chu ◽

Matthew J. Lin

Keyword(s):

Psychological Distress ◽

Long Term Results ◽

Treatment Modalities ◽

Line Treatment ◽

Review Of The Literature ◽

First Line ◽

Cosmetic Outcomes ◽

First Line Treatment ◽

Ablative Laser

Pearly penile papules (PPPs) are benign, dome-shaped lesions found around the corona of the penis. Despite being asymptomatic and benign in nature, the appearance of PPPs may cause a great deal of psychological distress to both the patient and their sexual partner. While patient reassurance may be the first-line treatment, several other treatment modalities including cryotherapy, electrodessication and curettage, and laser therapy have all been used to treat PPPs in order to achieve a cosmetic outcome that satisfies the patient. Based on the evaluation of the existing literature, ablative laser therapies offer satisfactory cosmetic outcomes with good long-term results.

Download Full-text

Major response to temozolomide as first-line treatment for newly-diagnosed DDR2-mutated glioblastoma: A case report

Revue Neurologique ◽

10.1016/j.neurol.2019.09.007 ◽

2020 ◽

Vol 176 (5) ◽

pp. 402-404

Author(s):

K. El Husseini ◽

F. Marguet ◽

A. Lamy ◽

N. Magne ◽

M. Fontanilles

Keyword(s):

Case Report ◽

Line Treatment ◽

Newly Diagnosed ◽

First Line ◽

Major Response ◽

First Line Treatment

Download Full-text

Biologic Therapy as a First-Line Treatment in Patients with Psoriasis: An Unstudied Population

Actas Dermo-Sifiliográficas (English Edition) ◽

10.1016/j.adengl.2018.06.022 ◽

2018 ◽

Vol 109 (7) ◽

pp. 579

Author(s):

O. Baniandrés Rodríguez

Keyword(s):

Biologic Therapy ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

California rocket fuel: And what about being a first line treatment?

European Psychiatry ◽

10.1016/j.eurpsy.2016.01.2033 ◽

2016 ◽

Vol 33 (S1) ◽

pp. S551-S551

Author(s):

J. Silva ◽

J. Mota ◽

P. Azevedo

Keyword(s):

Case Report ◽

Depressive Symptoms ◽

Case Reports ◽

Drug Resistant ◽

Line Treatment ◽

First Line ◽

Depressed Woman ◽

Rocket Fuel ◽

Resistant Depression ◽

First Line Treatment

IntroductionThe association venlafaxine-mirtazapine is currently known as California Rocket Fuel (CRF). Studies show advantage in terms of efficacy and rapid control of depressive symptoms compared to other associations. Venlafaxine is a selective serotonin-noradrenalin reuptake inhibitor and mirtazapine is a noradrenergic-specific serotonergic antidepressant: the result is a potent noradrenergic and serotonergic effect. Studies say that CRF should be performed only for drug-resistant depression; however, there are case reports of its use as a first line treatment, in selected patients.ObjectivesTo summarize the latest literature about this field and to present a case report.AimTo explore and critically review the controversies of venlafaxine-mirtazapine association as a first line antidepressants strategy.MethodsA brief review of the latest literature was performed, using PubMed and the keywords “venlafaxine-mirtazapine association”. A case report about a depressed woman is presented.ResultsDespite most studies are referent to its utility in drug-resistant depression, there are recent pilot studies that recommend CRF as a first line option.M., a 64-year-old woman, had her first psychiatric consultation. She had been depressed for 2 years, she lost 10 kg, had total insomnia and suicidal thoughts. CRF was started up to 150/15 mg, daily. An improvement was noticed after two weeks of treatment and the stabilization of depressive symptoms were achieved by the fourth month.ConclusionsCRF seems to be effective and useful. Patients with insomnia and weight loss may benefit from CRF as a first line option. However, more studies are needed.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text